AMG-208
Star0
Identification
- Generic Name
- AMG-208
- DrugBank Accession Number
- DB08079
- Background
AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 383.4027
Monoisotopic: 383.138224813 - Chemical Formula
- C22H17N5O2
- Synonyms
- 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
- External IDs
- AMG 208
- AMG-208
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UHepatocyte growth factor receptor inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyridazines. These are organic compounds containing a pyridazine ring substituted by a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyridazines and derivatives
- Direct Parent
- Phenylpyridazines
- Alternative Parents
- Quinolines and derivatives / Triazolopyridazines / Anisoles / Alkyl aryl ethers / Pyridines and derivatives / Benzene and substituted derivatives / Triazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds show 2 more
- Substituents
- 1,2,4-triazole / Alkyl aryl ether / Anisole / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative show 10 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y2SR66P7VM
- CAS number
- 1002304-34-8
- InChI Key
- HEAIZQNMNCHNFD-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
- IUPAC Name
- 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline
- SMILES
- COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 24864821
- PubChem Substance
- 99444550
- ChemSpider
- 21486186
- BindingDB
- 24470
- ChEBI
- 90626
- ChEMBL
- CHEMBL496102
- ZINC
- ZINC000034285235
- PDBe Ligand
- L5G
- PDB Entries
- 3cd8
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Withdrawn Treatment Prostate Cancer 1 1 Completed Treatment Advanced Malignant Neoplasm / Advanced Solid Tumors / Cancer / Cancer Patient / Oncology / Tumor 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0115 mg/mL ALOGPS logP 3.66 ALOGPS logP 3.37 Chemaxon logS -4.5 ALOGPS pKa (Strongest Basic) 6.17 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 74.43 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 119.54 m3·mol-1 Chemaxon Polarizability 40.72 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.976 Caco-2 permeable + 0.5 P-glycoprotein substrate Non-substrate 0.611 P-glycoprotein inhibitor I Non-inhibitor 0.7973 P-glycoprotein inhibitor II Inhibitor 0.5276 Renal organic cation transporter Non-inhibitor 0.5178 CYP450 2C9 substrate Non-substrate 0.6976 CYP450 2D6 substrate Non-substrate 0.7656 CYP450 3A4 substrate Substrate 0.5882 CYP450 1A2 substrate Inhibitor 0.7736 CYP450 2C9 inhibitor Non-inhibitor 0.7515 CYP450 2D6 inhibitor Non-inhibitor 0.915 CYP450 2C19 inhibitor Inhibitor 0.6341 CYP450 3A4 inhibitor Inhibitor 0.5541 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7706 Ames test Non AMES toxic 0.5 Carcinogenicity Non-carcinogens 0.9203 Biodegradation Not ready biodegradable 0.9907 Rat acute toxicity 2.2850 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7437 hERG inhibition (predictor II) Non-inhibitor 0.8498
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-dccb682973afe52095a0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0239000000-757c0d689fd1c6687aed Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-7393fbef5b40acdaea73 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0ue9-0209000000-47de6c0ac8d4e61af5da Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0fmi-1911000000-c51d8b84b835bad6f81e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-000x-3913000000-3dc2ddb52f830e393311 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 203.9400206 predictedDarkChem Lite v0.1.0 [M-H]- 192.60802 predictedDeepCCS 1.0 (2019) [M+H]+ 204.8358206 predictedDarkChem Lite v0.1.0 [M+H]+ 194.96602 predictedDeepCCS 1.0 (2019) [M+Na]+ 204.2256206 predictedDarkChem Lite v0.1.0 [M+Na]+ 201.37042 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsHepatocyte growth factor receptor
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein tyrosine kinase activity
- Specific Function
- Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including...
- Gene Name
- MET
- Uniprot ID
- P08581
- Uniprot Name
- Hepatocyte growth factor receptor
- Molecular Weight
- 155540.035 Da
References
- Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P: A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706. doi: 10.18632/oncotarget.4472. [Article]
Drug created at September 15, 2010 21:28 / Updated at June 12, 2020 16:52